Ranbaxy Laboratories enters into strategic alliance with Zenotech

By Lisa Kerner

Erie, Pa., March 9 - Ranbaxy Laboratories Ltd. said it has entered into a strategic alliance with Zenotech Laboratories Ltd., India.

The semi-exclusive agreement calls for Ranbaxy to market Zenotech's oncology cytotoxic injectable products under the Ranbaxy label in key Latin American markets, including Brazil and Mexico, and in Russia, according to a company news release.

Zenotech will develop and manufacture the oncology products at its dedicated facilities in India.

"We welcome this opportunity to join hands with Zenotech towards establishing a relationship that will complement each others' strengths," Peter Burema, president of Ranbaxy's Europe, Africa, CIS and Latin America division, said in the release.

"The alliance facilitates Ranbaxy's entry into this new therapeutic segment in these key markets."

Ranbaxy, an India-based pharmaceutical company, produces generic drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.